Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anoro

- PMLiVE

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe

- PMLiVE

GSK’s consumer health spin-off Haleon starts trading with £31bn market valuation

The company finalised its demerger of the Consumer Healthcare business group to form the new organisation

- PMLiVE

GSK creates new consumer healthcare business, Haleon

Haleon, whose brand portfolio will include Sensodyne toothpaste and Panadol painkillers, is the combination of the consumer health businesses of GSK and Pfizer

- PMLiVE

GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner

The Foundation will receive a £70,000 grant to improve access, education and support for underserved communities

- PMLiVE

Sanofi and GSK report positive data for COVID-19 Beta vaccine

Results from stage 1 and stage 2 of the study showed a favourable safety and tolerability profile

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

GSK unveils its brand identity as it demerges from Haleon

The new logo has been posted online, alongside news of a renewed company strategy and purpose

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

- PMLiVE

GSK appoint Tony Wood as chief scientific officer

Wood’s appointment will follow the exit of Dr Hal Barron, effective from August 2022

- PMLiVE

Sanofi/GSK vaccine boosts immune response

The vaccine boosted neutralising antibodies by 9 to 43-fold regardless of which vaccine was given as a primary course

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links